Exploring the Effects of Caltrate Supplement on the Chronic Course of Ulcerative Colitis Patients With Vitamin D Deficiency
Exploring the Effects of Caltrate Supplement on the Chronic Course of Ulcerative Colitis Patients With Vitamin D Deficiency
Aims:Prospectively observe the effects of Caltrate supplementation on the chronic course of
 ulcerative colitis patients, analyze whether the effect of Caltrate on UC patients is
 affected by factors such as disease site, disease activity, treatment, etc.Provide a certain
 theoretical basis for "precision treatment" for UC patients in the future.

 Design：It is a prospective cohort study. Investigators include a total of 60 participants
 with UC according to the inclusion and exclusion criteria, and divide them into two groups to
 assess their initial disease activity and detect related indicators. At the same
 time，Investigators detect the Vitamin D Gene gene polymorphisms in all participants.One group
 is given Caltrate 0.6g per day orally, and the control group do not intervene. After 12
 months, re-evaluate the disease activity and retest the relevant indicators, and use
 statistical methods to analyze whether Caltrate supplementation treatment can increase the
 serum 25 (OH) D level of UC participants, improve the condition of UC
 participants,relationship with Vitamin D Gene Polymorphism，and analyze the effects of
 Caltrate on participants with UC is affected by factors such as disease site, disease
 activity, and treatment.
1. The research can be started only after approval by the Medical Ethics Committee of the
 Second Affiliated Hospital of Wenzhou Medical University.

 2. According to the "Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease"
 formulated by the Beijing Conference in 2018 as a standard, patients with clear
 diagnosis of UC are collected. Exclusion criteria included pregnancy, breastfeeding,
 liver and kidney dysfunction, concurrent autoimmune diseases, and use of antiepileptic
 drugs or drugs metabolized by liver cytochrome P450 enzymes.

 3. Assess disease activity of UC participants based on the "Moya score".

 4. General information about participants with UC is collected.

 5. Detection of VDR gene polymorphisms using Snapshot technology.

 6. Serum C-reactive protein, erythrocyte sedimentation rate, white blood cells, albumin,
 creatinine, alanine aminotransferase, calcium and phosphorus levels are measured.

 7. The level of serum 25 (OH) D of participants is detected.

 8. Develop a treatment plan for participants.

 9. Participants are divided into two groups, one group is given oral Caltrate 0.6g / d, and
 the other group did not intervene.

 10. The above serum indicators are re-measured in the 12th month, and the condition of UC
 participants is also evaluated.

 11. Follow-up for 12 months. By comparing the above indicators, observe that in the Han
 population:

 1. Can Caltrate supplementation increase serum 25 (OH) D levels in patiens with UC?

 2. Can Caltrate supplementation improve the condition of patients with UC?

 3. Whether vitamin D gene polymorphisms affect the efficacy of Caltrate
 supplementation therapy?

 4. whether the effect of Caltrate on UC patients is affected by factors such as
 disease site, disease activity, treatment, etc ..

 12. Through statistical analysis, comprehensive analysis of the effectiveness and safety of
 Caltrate supplementation in Han patients with UC, and its relationship with vitamin D
 gene polymorphisms, providing a theoretical basis for further "precise treatment"
 intervention in inflammatory bowel disease.
Inclusion Criteria:

 -  Clearly diagnosed patients with UC

 -  Vitamin D deficiency (<= 20ng / ml)

 Exclusion Criteria:

 -  Pregnancy, lactation

 -  Liver and kidney insufficiency

 -  Co-morbid with other autoimmune diseases

 -  Use antiepileptic drugs or drugs metabolized by liver cytochrome P450 enzymes

 -  Vitamin D level is normal or high